case_images: PMC11263021_01
case_images: PMC11263021_02
case_images: PMC11263021_03
case_images: PMC11263021_04
case_images: PMC11263021_05
case_images: PMC11263021_06
case_images: Changes in skin lesions and skin vascularity during upadacitinib treatment. (A) Case 1, skin lesions at 0 and 4 weeks of upadacitinib treatment. (B) Case 2, skin lesions at 0 and 4 weeks of upadacitinib treatment. (C) Case 1, skin vascularity at 0 and 4 weeks of upadacitinib treatment. (D) Case 2, skin vascularity at 0 and 4 weeks of upadacitinib treatment.
case_images: fimmu-15-1416004-g001.jpg
case_images: PMC11263021_06_fimmu-15-1416004-g001.jpg
case_images: f1
case_images: During the therapeutic period, the patient's facial erythema disappeared significantly ( Figures 1A, C ). During the 4 weeks of treatment with upadacitinib, this patient reported significant improvement in facial erythema, tingling, flushing, pruritus, and dry symptoms ( Figures 1B, D ). During the 16 weeks of treatment with abrocitinib, this patient only showed mild improvement in pruritus, with no significant improvement in burning and tingle symptoms and no significant improvement in quality of life ( Supplementary Figure 1A ). During the 12 weeks of treatment with abrocitinib, this patient showed no significant improvement in symptoms or quality of life ( Supplementary Figure 1B ).
case_images: Changes in psychological well-being and quality of life, as well as clinical manifestations and signs, during upadacitinib treatment. (A) Case 1. (B) Case 2.
case_images: fimmu-15-1416004-g002.jpg
case_images: PMC11263021_06_fimmu-15-1416004-g002.jpg
case_images: f2
case_images: Moreover, notable enhancements were noted in the patient's psychological well-being and overall quality of life, paralleled by the gradual abatement of symptoms including erythema, flushing, and pruritus ( Figure 2A ). Moreover, this patient reported noteworthy improvements in changes in psychological well-being and quality-of-life ( Figure 2B ).
case_images: Changes of skin lesions and skin vascularity during abrocitinib treatment. (A) Case 3, skin lesions at 0, 4, 8, and 12 weeks of abrocitinib treatment. (B) Case 4, skin lesions at 0, 4, 8, and 12 weeks of abrocitinib treatment. (C) Case 3, skin vascularity at 0, 4, 8, and 12 weeks of abrocitinib treatment. (D) Case 4, skin vascularity at 0, 4, 8, and 12 weeks of abrocitinib treatment.
case_images: fimmu-15-1416004-g003.jpg
case_images: PMC11263021_06_fimmu-15-1416004-g003.jpg
case_images: f3
case_images: After 4 weeks of treatment with abrocitinib, this patient reported improvement in pruritus and life quality ( Figures 3A, 3C ,  4A ). During the 20-week treatment of abrocitinib, this patient only showed mild improvement in pruritus and no significant improvement in quality of life ( Figures 3B, 3D ,  4B ).
case_images: Changes in psychological well-being and quality of life, as well as clinical manifestations and signs during abrocitinib treatment. (A) Case 3. (B) Case 4.
case_images: fimmu-15-1416004-g004.jpg
case_images: PMC11263021_06_fimmu-15-1416004-g004.jpg
case_images: f4
case_images: After 4 weeks of treatment with abrocitinib, this patient reported improvement in pruritus and life quality ( Figures 3A, 3C ,  4A ). During the 20-week treatment of abrocitinib, this patient only showed mild improvement in pruritus and no significant improvement in quality of life ( Figures 3B, 3D ,  4B ).